Madison’s Exact Sciences Corp. reported a first-quarter loss of $110.2 million Wednesday, according to the Wisconsin State Journal. The loss matched analyst projections, although the company’s revenue of $637.5 million was higher than expected.
Adjusted for costs related to mergers and acquisitions and asset impairment costs, losses for the maker of the Cologuard colon cancer test equated to $0.50 per share, matching estimates from analysts surveyed by Zacks Investment Research. Meanwhile, analysts had expected company revenue of only $624.9 million.
Exact Sciences predicts its total 2024 revenue to fall between $2.81–2.85 billion.
